Generating large libraries of barcoded beads using combined partition pool strategy and chemical ligation
The combined segmentation pool method is used to attach oligonucleotide sequences round by round, and the problem of insufficient number of unique beads in the bead array is solved, which increases the number of beads and solves the informatics conflict in the bead array, and improves spatial transcription Capture of omic information.
Patent Information
- Application Number
- CN202380031482.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-29
- Filing Date
- 2023-12-28
- Publication Date
- 2024-11-26
AI Technical Summary
The insufficient number of unique bead types in existing bead arrays leads to informatics conflicts and fails to effectively capture the spatial transcriptomic information of the tissue.
Using a combined segmentation pool method, new oligonucleotide sequences are attached round by chemical ligation, and the barcode library is extended to ensure that each bead has a unique nucleotide sequence, thereby generating a large number of unique oligonucleotide barcode beads. .
A significant increase in the number of beads in the bead array was achieved, ensuring that each bead has a unique oligonucleotide sequence, solving the informatics conflict problem, and improving the ability to capture spatial transcriptomic information.
Smart Images

Figure BDA0005064669710000211 
Figure BDA0005064669710000221 
Figure HDA0005064669720000011
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority under 35 USC §119(e) to U.S. Provisional Application No. 63 / 477,747, filed on December 29, 2022, which is incorporated herein by reference in its entirety. Background Art
[0003] Spatially resolved genomics and transcriptomics are areas of high interest but are limited by the challenge of generating diverse bead arrays containing beads with unique oligonucleotide sequences relative to each other. Summary of the invention
[0004] Bead arrays can be used with spatial genomics and transcriptomics, but one drawback is the insufficient number of unique bead types (i.e., beads containing unique nucleotide sequences). Typically, multiple beads in a bead array contain identical nucleotide sequences that cause informatics conflicts. In order to be able to use bead arrays as substrates to capture spatial transcriptomics information of tissues, each bead on the array needs to have a unique barcode so that the attached oligonucleotides can be identified as unique sequences during the bead array decoding process.
[0005] In order to be compatible with existing bead array substrate configurations, a large number (e.g., 50 million to 500 million) of bead types are required. To achieve such a large number of bead types, the present disclosure provides a combinatorial split pooling method in which chemical ligation is performed during each round of splitting to attach new oligonucleotide sequences, thereby expanding the barcode library.
[0006] Thus, in some aspects, the present disclosure provides a method of producing a bead array, the method comprising: (i) attaching a first oligonucleotide to a first population of beads, attaching a second oligonucleotide to a second population of beads, and attaching a third oligonucleotide to a third population of beads, wherein the first oligonucleotide, the second oligonucleotide, and the third oligonucleotide comprise unique nucleotide sequences relative to each other; (ii) combining the first population of beads, the second population of beads, and the third population of beads to produce a first pool; (iii) dividing the first pool into a first plurality of aliquots; (iv) in a first aliquot of the first plurality of aliquots, chemically linking a fourth oligonucleotide to the first oligonucleotide in the presence of a first splint oligonucleotide, wherein the fourth oligonucleotide a splint oligonucleotide that hybridizes to both the fourth oligonucleotide and the first oligonucleotide; chemically ligates to the second oligonucleotide in the presence of a second splint oligonucleotide, wherein the second splint oligonucleotide hybridizes to both the fourth oligonucleotide and the second oligonucleotide; chemically ligates to the third oligonucleotide in the presence of a third splint oligonucleotide, wherein the third splint oligonucleotide hybridizes to both the fourth oligonucleotide and the third oligonucleotide; wherein the first splint oligonucleotide, the second splint oligonucleotide, and the third splint oligonucleotide comprise unique nucleotide sequences relative to each other; in a second aliquot of the first plurality of aliquots, chemically ligates to the first oligonucleotide in the presence of the fourth splint oligonucleotide, wherein the fourth splint oligonucleotide hybridizes to The fifth oligonucleotide is hybridized to both the first oligonucleotide and the second oligonucleotide; chemically linked to the second oligonucleotide in the presence of the fifth splint oligonucleotide, wherein the fifth splint oligonucleotide is hybridized to both the fifth oligonucleotide and the second oligonucleotide; chemically linked to the third oligonucleotide in the presence of the sixth splint oligonucleotide, wherein the sixth splint oligonucleotide is hybridized to both the fifth oligonucleotide and the third oligonucleotide; wherein the fourth splint oligonucleotide, the fifth splint oligonucleotide and the sixth splint oligonucleotide comprise unique nucleotide sequences relative to each other; and in a third aliquot of the first plurality of aliquots, the sixth oligonucleotide is: chemically linked to the first oligonucleotide in the presence of the seventh splint oligonucleotide, wherein the seventh splint oligonucleotide is hybridized to the sixth oligonucleotide and the third oligonucleotide; (v) combining a first aliquot of the first plurality of aliquots, a second aliquot of the first plurality of aliquots, and a third aliquot of the first plurality of aliquots to produce a second pool; (vi) dividing the second pool into a second plurality of aliquots;(vii) in a first aliquot of the second plurality of aliquots, chemically linking the seventh oligonucleotide to the fourth oligonucleotide in the presence of the tenth split oligonucleotide, wherein the tenth split oligonucleotide hybridizes to both the seventh oligonucleotide and the fourth oligonucleotide; in a second aliquot of the second plurality of aliquots, chemically linking the eighth oligonucleotide to the fifth oligonucleotide in the presence of the eleventh split oligonucleotide, wherein the eleventh split oligonucleotide hybridizes to both the eighth oligonucleotide and the fifth oligonucleotide; and in a third aliquot of the second plurality of aliquots, chemically linking the ninth oligonucleotide to the sixth oligonucleotide in the presence of the twelfth split oligonucleotide, wherein the twelfth split oligonucleotide hybridizes to both the ninth oligonucleotide and the sixth oligonucleotide, and wherein the tenth split oligonucleotide, the eleventh split oligonucleotide, and the twelfth split oligonucleotide comprise unique nucleotide sequences relative to each other. In some embodiments, the method further comprises: (viii) combining a first aliquot of the second plurality of aliquots, a second aliquot of the second plurality of aliquots, and a third aliquot of the second plurality of aliquots to produce a third pool; (ix) dividing the third pool into a third plurality of aliquots; (x) in the first aliquot of the third plurality of aliquots, chemically linking the tenth oligonucleotide to the seventh oligonucleotide in the presence of the thirteenth splint oligonucleotide, wherein the thirteenth splint oligonucleotide hybridizes with both the tenth oligonucleotide and the seventh oligonucleotide; in the second aliquot of the third plurality of aliquots, chemically linking the eleventh oligonucleotide to the eighth oligonucleotide in the presence of the fourteenth splint oligonucleotide, wherein the fourteenth splint oligonucleotide hybridizes with both the eleventh oligonucleotide and the eighth oligonucleotide; and in the third aliquot of the third plurality of aliquots, chemically linking the twelfth oligonucleotide to the ninth oligonucleotide in the presence of the fifteenth splint oligonucleotide, wherein the fifteenth splint oligonucleotide hybridizes with both the twelfth oligonucleotide and the ninth oligonucleotide, and wherein the thirteenth splint oligonucleotide, the fourteenth splint oligonucleotide, and the fifteenth splint oligonucleotide comprise unique nucleotide sequences relative to each other. In other aspects, the present disclosure provides a method of producing a bead array, the method comprising: (i) attaching a first oligonucleotide to one or more beads in a first bead population, attaching a second oligonucleotide to one or more beads in a second bead population, and attaching a third oligonucleotide to one or more beads in a third bead population, wherein the first oligonucleotide, the second oligonucleotide, and the third oligonucleotide comprise unique nucleotide sequences relative to each other; (ii) combining the first bead population, the second bead population, and the third bead population to produce a first pool; (iii) dividing the first pool into a first plurality of aliquots; (iv) in a first aliquot of the first plurality of aliquots, chemically linking a fourth oligonucleotide to the first oligonucleotide, the second oligonucleotide, and the third oligonucleotide;In the second aliquot of the first plurality of aliquots, the fifth oligonucleotide is chemically linked to the first oligonucleotide, the second oligonucleotide and the third oligonucleotide; and in the third aliquot of the first plurality of aliquots, the sixth oligonucleotide is chemically linked to the first oligonucleotide, the second oligonucleotide and the third oligonucleotide; (v) the first aliquot of the first plurality of aliquots, the second aliquot of the first plurality of aliquots and the third aliquot of the first plurality of aliquots are combined to produce a second pool; (vi) the second pool is divided into a second plurality of aliquots; (vii) in the first aliquot of the second plurality of aliquots, the seventh oligonucleotide is chemically linked to the fourth oligonucleotide; in the second aliquot of the second plurality of aliquots, the eighth oligonucleotide is chemically linked to the fifth oligonucleotide; and in the third aliquot of the second plurality of aliquots, the ninth oligonucleotide is chemically linked to the sixth oligonucleotide. In some embodiments, the method further comprises (viii) combining a first aliquot of the plurality of second aliquots, a second aliquot of the plurality of second aliquots, and a third aliquot of the plurality of second aliquots to produce a third pool; (ix) dividing the third pool into a third plurality of aliquots; (x) chemically linking the tenth oligonucleotide to the seventh oligonucleotide in the first aliquot of the third plurality of aliquots; chemically linking the eleventh oligonucleotide to the eighth oligonucleotide in the second aliquot of the second plurality of aliquots; and chemically linking the twelfth oligonucleotide to the ninth oligonucleotide in the third aliquot of the second plurality of aliquots. In some embodiments, the method produces a bead array comprising at least about 1×10; 6 In other embodiments, the method produces an array of beads comprising at least about 1×10 7 In yet other embodiments, the method produces an array of beads comprising at least about 1×10 8In some embodiments, the first splint oligonucleotide, the second splint oligonucleotide, the third splint oligonucleotide, the fourth splint oligonucleotide, the fifth splint oligonucleotide, the sixth splint oligonucleotide, the seventh splint oligonucleotide, the eighth splint oligonucleotide, the ninth splint oligonucleotide, the tenth splint oligonucleotide, the eleventh splint oligonucleotide, and the twelfth splint oligonucleotide have the same nucleotide sequence. In some embodiments, the first splint oligonucleotide, the second splint oligonucleotide, the third splint oligonucleotide, the fourth splint oligonucleotide, the fifth splint oligonucleotide, the sixth splint oligonucleotide, the seventh splint oligonucleotide, the eighth splint oligonucleotide, the ninth splint oligonucleotide, the tenth splint oligonucleotide, the eleventh splint oligonucleotide, the twelfth splint oligonucleotide, the thirteenth splint oligonucleotide, the fourteenth splint oligonucleotide, and the fifteenth splint oligonucleotide have the same nucleotide sequence. In various embodiments, an oligonucleotide comprising (i) a poly(T) or poly(A) nucleotide sequence; (ii) one or more gene-specific capture sequences; (iii) one or more universal capture sequences (e.g., a random nucleotide sequence or a semi-random nucleotide sequence) or a combination thereof is chemically attached to the end of each oligonucleotide on each bead in the bead array. In some embodiments, (i) comprises about 100 bead populations, each bead population comprising a unique oligonucleotide attached thereto relative to each other bead population. In other embodiments, (i) comprises about 13,600 bead populations, and each bead population comprises a unique oligonucleotide attached thereto relative to each other bead population. In some embodiments, the first oligonucleotide, the second oligonucleotide, and / or the third oligonucleotide are attached to one or more beads via a cleavable linker. In various embodiments, prior to chemical attachment, a 3′-modified nucleotide is incorporated using terminal deoxynucleotidyl transferase (TdT). In some embodiments, one or more of the first oligonucleotide, the second oligonucleotide, the third oligonucleotide, the fourth oligonucleotide, the fifth oligonucleotide, the sixth oligonucleotide, the seventh oligonucleotide, the eighth oligonucleotide or the ninth oligonucleotide is a barcode. In other embodiments, each of the first oligonucleotide, the second oligonucleotide, the third oligonucleotide, the fourth oligonucleotide, the fifth oligonucleotide, the sixth oligonucleotide, the seventh oligonucleotide, the eighth oligonucleotide and the ninth oligonucleotide is a barcode. In some embodiments, one or more of the tenth oligonucleotide, the eleventh oligonucleotide or the twelfth oligonucleotide is a barcode. In other embodiments, each of the tenth oligonucleotide, the eleventh oligonucleotide and the twelfth oligonucleotide is a barcode. In other embodiments, the barcode is a spatial barcode. BRIEF DESCRIPTION OF THE DRAWINGS
[0007] Figure 1A general schematic diagram of an exemplary combined splitting and pooling method of the present disclosure for bead pool generation is depicted. In each splitting and pooling step, an oligonucleotide is ligated (eg, chemically ligated) to the end of a growing barcode strand.
[0008] Figure 2 Various non-limiting examples of non-natural backbone bonds that can be used for library synthesis are shown (1 to 7: triazole, 8: squaramide, 9: urea).
[0009] Figure 3 Shown are a) phosphate or phosphate derivative bonds for chemical ligation, b) non-limiting examples of the types of chemistries that can be used to generate phosphate-derived backbones in chemical ligation.
[0010] Figure 4 The structures of various 3' and 5' modifications are shown, which can be used Figure 2 The non-natural but biocompatible backbone shown in .
[0011] Figure 5 An illustrative workflow for barcode generation using TdT enzyme incorporation of modified nucleotides capable of chemical ligation is shown. SM = surface modification. CL = cleavable linker. The "N" in the phrase "N number of sequences of unique barcodes on the bead" refers to the number of times chemical ligation occurs.
[0012] Figure 6 An illustrative workflow for barcode generation using only chemical ligation without TdT is shown. SM = surface modification. CL = cleavable linker. The "N" in the phrase "N number of sequences of unique barcodes on the bead" refers to the number of times chemical ligation occurs.
[0013] Figure 7 An illustrative workflow for protection involving one reactive group with two chemical handles for protection is depicted.
[0014] Figure 8 An illustrative workflow involving two pairs of orthogonal reactive groups (four chemical reaction handles) is depicted.
[0015] Fig. 9 A schematic diagram of oligonucleotide ligation using a splint is depicted. R1 and R2 are functional groups used for chemical ligation.
[0016] Fig.10 Depicted are non-limiting examples of chemically cleavable attachments that can be used for attachment of barcodes to beads and, optionally, subsequent cleavage from the beads for sequencing.
[0017] Fig.11Depicted are the types of splint oligonucleotides contemplated by the present disclosure. a) Universal bridge sequence. Nucleotide sequences A′ and B′ are universal sequences that hybridize with nucleotide sequences A and B of the universal bridge sequence. Nucleotide sequence C is a unique Oligo Seq 1 sequence. Nucleotide sequence D is a unique Oligo Seq 2 sequence. Nucleotide sequence E is a unique Oligo Seq 3 sequence. b) Unique bridge sequence. Nucleotide sequences A′ and B′ are unique sequences that hybridize with nucleotide sequences A and B of the first unique bridge sequence. Similarly, nucleotide sequences G′ and H′ are unique nucleotide sequences that hybridize with nucleotide sequences G and H of the second unique bridge sequence. Nucleotide sequence A′, nucleotide sequence B′, nucleotide sequence G′, nucleotide sequence H′, nucleotide sequence F′, and nucleotide sequence I′ are each unique nucleotide sequences relative to each other. Nucleotide sequence C is a unique Oligo Seq 1 sequence. Nucleotide sequence D is a unique Oligo Seq 2 sequence. Nucleotide sequence E is a unique Oligo Seq 3 sequence. R1 and R2 are functional groups for chemical attachment. DETAILED DESCRIPTION
[0018] The present disclosure generally relates to a method for producing a pool of beads by a combined segmentation pool strategy. Oligonucleotides on a bead array are generally all synthesized before being attached to beads. However, producing a large number of unique oligonucleotide barcoding beads will require the synthesis of a large number of species of longer oligonucleotide sequences. The synthesis of large oligonucleotides presents a significant challenge and often results in a reduction in yield. Therefore, the present disclosure provides a method for producing a large unique oligonucleotide sequence pool using a combined segmentation pool and connection (e.g., chemical connection). Figure 1 A general, non-limiting schematic diagram of the methods of the present disclosure is provided in .
[0019] the term
[0020] As used in this specification and the enumerated paragraphs herein, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise.
[0021] "About" and "approximately" generally refer to an acceptable degree of error for the amount measured given the nature or precision of the measurement. Exemplary degrees of error are within 20-25% of the value or range of values, such as within 20%, 10%, 5%, 4%, 3%, 2% or 1%.
[0022] The term "bead" refers to a small body made of a rigid or semi-rigid material. The body can have a shape characterized, for example, by spherical, ellipsoidal, microspherical, or other recognized particle shapes, whether of regular or irregular size. Exemplary materials that can be used for beads include, but are not limited to, glass; plastics such as acrylic, polystyrene or a copolymer of styrene and another material, polypropylene, polyethylene, polybutylene, polyurethane, or polytetrafluoroethylene (available from Chemours) ); polysaccharides or cross-linked polysaccharides, such as agarose or agarose gel; nylon; nitrocellulose; resins; silica or silica-based materials, including silicon and modified silicon; carbon fibers, metals; inorganic glass; fiber optic bundles, or a variety of other polymers. Exemplary beads include, but are not limited to, controlled pore glass beads, paramagnetic beads, thoria sols, Sepharose beads, nanocrystals, and other beads known in the art, such as those described in the Microsphere Detection Guide from Bangs Laboratories, Fishers Ind. The beads can also be coated with a polymer having a functional group that can be attached to an oligonucleotide.
[0023] As used herein, the term "solid carrier" refers to a rigid substrate that is insoluble in aqueous liquids. The substrate can be nonporous or porous. The substrate can optionally be capable of absorbing liquids (e.g., due to porosity), but will generally be rigid enough so that the substrate does not significantly expand when absorbing liquids and does not substantially shrink when the liquids are removed by drying. Nonporous solid carriers are generally impermeable to liquids or gases. Exemplary solid carriers include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylic acid, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethane, Teflon, polypropylene ... TM, cyclic olefins, polyimides, etc.), nylon, ceramics, resins, Zeonor, silica or silica-based materials (including silicon and modified silicon), carbon, metals, inorganic glasses, fiber bundles, and polymers. Particularly useful materials are glass. Other suitable substrate materials may include polymeric materials, plastics, silicon, quartz (fused quartz), borofloat glass, silica, silica-based materials, carbon, metals (including gold), optical fibers or fiber bundles, sapphire or plastic materials such as COC and epoxides. A specific material may be selected based on the properties desired for a particular use. For example, a material that is transparent to radiation of a desired wavelength may be used for analytical techniques that will utilize radiation of a desired wavelength, such as one or more of the techniques described herein. Conversely, it may be desirable to select a material that does not pass radiation of a specific wavelength (e.g., opaque, absorptive, or reflective). This can be used to form a mask to be used during the manufacture of a structured substrate; or for chemical reactions or analytical detection using a structured substrate. Other properties of the material that can be utilized are inertness or reactivity to certain reagents used in downstream processes; or ease of handling or low cost during manufacturing processing. Additional examples of materials that can be used in the structured substrates or methods of the present disclosure are described in US Patent Application Publication Nos. 2012 / 0316086A1 and 2013 / 0116153, each of which is incorporated herein by reference in its entirety. In some embodiments, the solid support is a flow cell as described below.
[0024] In any aspect or embodiment of the present disclosure, solid carrier can include the collection of beads or other particles. Particles can be suspended in solution, or they can be located on the surface of substrate. The example of array with beads located on the surface includes those arrays in which beads are located in holes, such as BeadChip array (Illumina Inc., San Diego Calif., San Diego Calif.) or for the substrate of the sequencing platform from 454LifeSciences (subsidiary of Roche, Basel Switzerland) or for the substrate of the sequencing platform from IonTorrent (subsidiary of Carlsbad Life Technologies, Calif., Carlsbad Calif.). Other solid supports with beads located on the surface are described in U.S. Patent Nos. 6,266,459; 6,355,431; 6,770,441; 6,859,570; 6,210,891; 6,258,568; or 6,274,320; U.S. Patent Application Publication Nos. 2009 / 0026082A1; 2009 / 0127589A1; 2010 / 0137143A1; or 2010 / 0282617A1 or PCT Publication No. WO 00 / 63437, each of which is incorporated herein by reference. Several of the above references describe methods for attaching nucleic acids to beads before loading beads into or on a solid support. However, it should be understood that the oligonucleotides to be connected can be prepared first and then attached to beads, which can then be loaded onto an array and used in the methods described herein. In some embodiments, the ligated oligonucleotides are released from beads and attached to a solid support (e.g., but not limited to, a flow cell). Therefore, the present invention also contemplates the use of a flow cell. As used herein, the term "flow cell" is intended to mean a container having a chamber in which a reaction can be performed, an inlet for delivering reagents to the chamber, and an outlet for removing reagents from the chamber. In some embodiments, the chamber is constructed to detect a reaction occurring in the chamber. For example, the chamber may include one or more transparent surfaces that allow optical detection of biological samples, optically labeled molecules, etc. in the chamber. Exemplary flow cells include, but are not limited to, those used in nucleotide sequencing devices, such as those used in Genome sequencing devices commercialized by Illumina (San Diego, California). or or for SOLiD commercialized by Life Technologies Corporation (Carlsbad, CA) TM or Ion Torrent TMFlow cells for sequencing platforms. Exemplary flow cells and methods of making and using the same are also described in, for example, WO 2014 / 142841 A1, US Patent Application Publication No. 2010 / 0111768 A1, and US Patent No. 8,951,781, each of which is incorporated herein by reference.
[0025] In some embodiments, a solid support commonly used for bead arrays is used without beads. For example, nucleic acids (such as oligonucleotides connected as described herein) can be directly attached to a gel material in a hole or well. Therefore, the above references are examples of materials, compositions, or devices that can be modified for use in methods and compositions described herein.
[0026] The solid support used in the method described herein can include a bead array, wherein the different oligonucleotides connected are attached to the different beads in the array. In various embodiments, each bead can be attached to the different oligonucleotides connected, and the beads can be randomly distributed on the solid support, so that different nucleic acid probes are effectively attached to the solid support.
[0027] Optionally, the solid support may include a hole having a size to accommodate no more than a single bead. In this configuration, the beads may be attached to the hole due to the force generated by the fit of the beads in the hole. Attachment chemicals or adhesives may also be used to hold the beads in the hole.
[0028] As described herein, the linked oligonucleotides attached to the beads can comprise or consist of a barcode sequence. According to the methods provided herein, a population of beads can be constructed such that each bead is attached to only one type of linked oligonucleotide comprising a plurality of barcodes, and many different beads (each bead having a different linked oligonucleotide) are present in the population.
[0029] As used herein, when used with reference to nucleic acids, the term "different" means that the nucleic acids have nucleotide sequences that are not identical to each other. Two or more nucleic acids may have nucleotide sequences that differ along their entire length. Alternatively, two or more nucleic acids may have nucleotide sequences that differ along a substantial portion of their length. For example, two or more nucleic acids may have target nucleotide sequence portions that are different for two or more molecules, while also having common sequence portions that are identical on the two or more molecules. The term can be similarly applied to proteins that can be distinguished as different from each other based on amino acid sequence differences.
[0030] "Complementary" means that an oligonucleotide comprises a nucleotide sequence that can form a double-stranded structure by matching base pairs with another oligonucleotide or a portion thereof. "Substantially complementary" means that an oligonucleotide has at least 85%, 90%, 95%, 98%, 99% or 100% overall sequence identity with a complementary sequence.
[0031] The bead array comprising oligonucleotides can also be used for sequencing procedures, such as sequencing by synthesis (SBS) technology. In short, SBS can be initiated by contacting a barcode with one or more labeled nucleotides, DNA polymerases, etc. The features of the sequence comprising the barcode as a template extension primer will be incorporated with the detected labeled nucleotides. Optionally, the labeled nucleotides can also include the reversible termination property that terminates further primer extension once nucleotides are added to the primer. For example, a nucleotide analog with a reversible terminator portion can be added to the primer so that subsequent extension does not occur until a deblocking agent is delivered to remove the portion. Therefore, for the embodiment using reversible termination, the deblocking agent can be delivered to the circulation cell (before or after detection occurs). Washing can be carried out between each delivery step. This cycle can then be repeated n times to extend the primer to n nucleotides, thus detecting a sequence of length n. Exemplary SBS procedures, fluid systems, and detection platforms that can be readily adapted for use with the methods of the present disclosure are described, for example, in Bentley et al., Nature 456:53-59 (2008); WO 04 / 018497; WO 91 / 06678; WO 07 / 123744; U.S. Pat. Nos. 7,057,026; 7,329,492; 7,211,414; 7,315,019 or 7,405,281, and U.S. Patent Application Publication No. 2008 / 0108082A1; each of which is incorporated herein by reference.
[0032] As used herein, "primer" is a nucleic acid molecule that can hybridize with a target sequence, such as an adapter attached to a library fragment. For example, an amplification primer can be used as a starting point for template amplification and cluster generation. For example, a synthetic nucleic acid (template) chain may include a site to which a primer (e.g., a sequencing primer) can hybridize, so as to initiate the synthesis of a new chain complementary to the synthetic nucleic acid chain. Any primer may include any combination of nucleotides or their analogs. In some examples, a primer is a single-stranded oligonucleotide or polynucleotide. Primer length can be any number of base lengths and can include a variety of non-natural nucleotides. In various embodiments, a sequencing primer is a short chain, ranging from 5 to 60 bases, 10 to 60 bases, 10 to 20 bases, 10 to 30 bases, 10 to 40 bases, 10 to 50 bases, or 20 to 40 bases.
[0033] As used herein, the term "unique molecular identifier" or "UMI" refers to a random, non-random, or semi-random molecular tag that can be attached to a nucleic acid. When incorporated into a nucleic acid, the UMI can be used to correct for subsequent amplification bias by directly counting the unique molecular identifiers (UMIs) sequenced after amplification. UMIs can be attached to similar nucleic acids (e.g., adapters) so that each nucleic acid is unique.
[0034] As used herein, the term "adapter" generally refers to any linear nucleic acid molecule that can be connected to an oligonucleotide of the present disclosure. In some embodiments, the adaptor includes two reverse complementary oligonucleotides that form a double-stranded structure. In some embodiments, the adaptor includes two oligonucleotides that are complementary at one portion and mismatched at another portion, thereby forming a Y-shaped or forked adaptor that is double-stranded at the complementary portion and has two soft overhangs at the mismatched portion.
[0035] As used herein, the term "barcode" is intended to represent a series of nucleotides in an oligonucleotide that can be used to identify an oligonucleotide, a spatial address on the surface, a feature of an oligonucleotide, or an operation performed on an oligonucleotide. A barcode can be a naturally occurring nucleotide sequence or a nucleotide sequence that is not naturally present in an organism from which a barcoded nucleic acid is obtained. A barcode sequence can be unique for a single nucleic acid species in a population, or a barcode sequence can be shared by several different nucleic acid species in a population. For example, each nucleic acid capture probe in a population for spatial capture of nucleic acids in a biological sample (e.g., a permeabilized tissue sample, a cell suspension) on a substrate can include different barcode sequences from all other nucleic acid capture probes in the population. Alternatively, each nucleic acid probe in a population can include different barcode sequences from some or most other nucleic acid capture probes in a population. For example, each capture probe in a population can have a barcode that exists for several different capture probes in a population, even if the capture probes with a common barcode are different from each other at other sequence regions along their lengths. In various embodiments, one or more barcode sequences for biological tissues are not present in the genome, transcriptome, or other nucleic acids of a biological sample. For example, a barcode sequence may have less than 80%, 70%, 60%, 50%, or 40% sequence identity to a nucleic acid sequence in a particular biological tissue.
[0036] As used herein, the term "array" refers to a group of sites that can be distinguished from each other according to relative positions. Different molecules located at different sites of an array can be distinguished from each other according to the position of the site in the array. A single site of an array may contain one or more specific types of molecules. For example, a site may contain a single nucleic acid molecule with a specific sequence, or a site may contain several nucleic acid molecules with the same sequence (and / or its complementary sequence). The sites of an array may be different features located on the same substrate. Exemplary features include, but are not limited to, beads (or other particles) in or on a substrate, droplets, holes in a substrate, protrusions of a substrate, ridges on a substrate, or channels in a substrate. The sites of an array may be separate substrates each with different molecules. Different molecules attached to a separate substrate may be identified according to the position of the substrate on a surface associated with the substrate, or according to the position of the substrate in a liquid or gel. Exemplary arrays in which separate substrates are located on the surface include, but are not limited to, those arrays with beads in holes.
[0037] As used herein, the term "tissue" is intended to mean an aggregate of cells and optional intercellular material. Typically, cells in a tissue are not free-floating in a solution, but are attached to each other to form a multicellular structure. Exemplary tissue types include muscle, nerve, epidermis, and connective tissue.
[0038] When referring to the example of adapters, the terms "P5" and "P7" may be used. The terms "P5'" (apostrophe on P5) and "P7'" (apostrophe on P7) refer to the complementary sequences of P5 and P7, respectively. It should be understood that any suitable adapter can be used in the methods presented herein, and the use of P5 and P7 is merely an exemplary embodiment. The use of adapters such as P5 and P7 or their complementary sequences on a circulation cell is known in the art, as exemplified by the disclosures of WO 2007 / 010251, WO 2006 / 064199, WO 2005 / 065814, WO2015 / 106941, WO 1998 / 044151 and WO 2000 / 018957, each of which is incorporated herein by reference in its entirety. For example, any suitable forward amplification primer, whether immobilized or in solution, can be used in the methods presented herein for hybridization with a complementary sequence and amplification of the sequence. Similarly, any suitable reverse amplification primer, whether immobilized or in solution, can be used in the methods presented herein for hybridizing with complementary sequences and amplifying sequences. Those skilled in the art will understand how to design and use primer sequences suitable for capturing and / or amplifying nucleic acids presented herein.
[0039] As used herein, the term "connection" and its derivatives generally refer to the process of covalently connecting two or more molecules together, such as covalently connecting two or more nucleic acid molecules to each other. In some embodiments, the connection includes an incision between adjacent nucleotides of the joined nucleic acid. In some embodiments, the connection includes forming a covalent bond between the end of the first oligonucleotide and the end of the second oligonucleotide. In some embodiments, the connection may include forming a covalent bond between the 5' phosphate group of an oligonucleotide and the 3' hydroxyl of the second oligonucleotide, thereby forming a connected nucleic acid molecule. As used herein, "connected oligonucleotides" refer to oligonucleotides produced after two or more rounds of the combined segmentation pool method of the present disclosure. Chemical connections of oligonucleotides are further described herein.
[0040] As used herein, "hybridize" is intended to mean that a first oligonucleotide and a second oligonucleotide non-covalently associate along the length of those polymers to form a double-stranded "duplex". For example, two DNA oligonucleotide chains can associate by complementary base pairing. The strength of association between the first oligonucleotide and the second oligonucleotide increases with the complementarity between the nucleotide sequences within those oligonucleotides. The hybridization strength between oligonucleotides can be characterized by a melting temperature (Tm), at which 50% of the duplexes have oligonucleotide chains that dissociate from each other. Oligonucleotides that "partially" hybridize to each other mean that they have sequences that are complementary to each other, but such sequences only hybridize to each other along a portion of their length to form a partial duplex. Oligonucleotides that "cannot" hybridize include those oligonucleotides that are physically separated from each other, so that the number of their bases is not enough to contact each other in a manner that hybridizes to each other.
[0041] As used herein, the term "multiple numbers" is intended to represent a population of two or more members, which may all be the same, or two or more members may be different. Multiple numbers may be in the range of small, medium, large to extremely large sizes. The size of a small multiple number may be in the range of, for example, several members to tens of members. A medium-sized multiple number may be in the range of, for example, tens of members to about 100 members or hundreds of members. A large multiple number may be in the range of, for example, about hundreds of members to about 1000 members, to thousands of members, and up to tens of thousands of members. Extremely large multiple numbers may be in the range of, for example, tens of thousands of members to about hundreds of thousands, one million, several million, tens of millions, and up to or exceeding hundreds of millions of members. Therefore, a plurality of numbers may be in the range of two to far more than 100 million members and all sizes as measured by the number of members, between the above exemplary ranges and exceeding the above exemplary ranges. Therefore, the definition of the term is intended to include all integer values greater than two. The upper limit of a plurality of numbers may be set, for example, by the theoretical diversity of the bead type in the array.
[0042] As used herein, the term "attachment" refers to the state in which two things are joined, fastened, adhered, connected or combined with each other. For example, an oligonucleotide can be attached to a material, such as a bead, by a covalent bond or a non-covalent bond. A covalent bond is characterized by sharing electron pairs between atoms. A non-covalent bond is a chemical bond that does not involve sharing electron pairs, and can include, for example, hydrogen bonds, ionic bonds, van der Waals forces, hydrophilic interactions, and hydrophobic interactions.
[0043] As used herein, a "semi-random" nucleotide sequence comprises or consists of a partially predetermined nucleotide sequence combined with a random nucleotide sequence.
[0044] Oligonucleotides
[0045] Oligonucleotide is a polymer comprising nucleotides. Oligonucleotides disclosed herein can have any length, and in various embodiments, include DNA oligonucleotides, RNA oligonucleotides, analogs thereof, or combinations thereof. In any aspect or embodiment described herein, the oligonucleotide is single-stranded, double-stranded, or partially double-stranded.
[0046] Nucleotides may include naturally occurring nucleotides and functional analogs thereof. Examples of functional analogs are those that can hybridize with nucleic acids in a sequence-specific manner or can be used as templates for replicating specific nucleotide sequences. Naturally occurring nucleotides typically have a backbone containing a phosphodiester bond. Similar structures may have alternative backbone bonds, including any of a variety of backbone bonds known in the art. Naturally occurring nucleotides typically have deoxyribose (e.g., present in DNA) or ribose (e.g., present in RNA). Similar structures may have alternative sugar moieties, including any of a variety of sugar moieties known in the art. Nucleotides may include natural or non-natural bases. Natural DNA may include one or more of adenine, thymine, cytosine and / or guanine, and natural RNA may include one or more of adenine, uracil, cytosine and / or guanine. Any non-natural bases may be used, such as locked nucleic acids (LNA) and bridge nucleic acids (BNA). Exemplary modified nucleotides include inosine, xathanine, hypoxanthine, isocytosine, isoguanine, 2-aminopurine, 5-methylcytosine, 5-hydroxymethylcytosine, 2-aminoadenine, 6-methyladenine, 6-methylguanine, 2-propylguanine, 2-propyladenine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 15-halouracil, 15-halocytosine, 5-propynyluracil, 5-propynylcytosine, 6-azouracil, In some embodiments, the nucleotide analogs of the present invention can be substituted with 5'- 5'- pyrimidine, 6-azocytosine, 6-azothymine, 5-uracil, 4-thiouracil, 8-halogenated adenine or guanine, 8-aminoadenine or guanine, 8-thiol adenine or guanine, 8-sulfanyl adenine or guanine, 8-hydroxyadenine or guanine, 5-halogenated uracil or cytosine, 7-methylguanine, 7-methyladenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, 3-deazaadenine, etc. As known in the art, some nucleotide analogs cannot be incorporated into polynucleotides, for example, nucleotide analogs such as 5'-phosphosulfate adenosine. Nucleotide can include any suitable number of phosphates, for example, three, four, five, six or more than six phosphates.
[0047] The oligonucleotides contemplated by the present disclosure also include those with at least one modified internucleotide bond. In some embodiments, the oligonucleotide is a peptide nucleic acid in whole or in part. The internucleoside bond of other modifications includes at least one phosphorothioate bond. The oligonucleotides of other modifications include those comprising one or more universal bases. "Universal base" refers to a molecule that can replace the combination of any one of A, C, G, T and U in nucleic acid by forming a hydrogen bond without significant structural destabilization. Examples of universal bases include but are not limited to 5'-nitroindole-2'-deoxynucleoside, 3-nitropyrrole, inosine and hypoxanthine.
[0048] method
[0049] The present disclosure generally relates to methods for producing a large library of barcoded beads using a combined split pool strategy and connection (e.g., chemical connection). Generally, the method includes continuous rounds of adding oligonucleotides (e.g., barcodes) to the growing oligonucleotide chain. Continuous rounds of adding oligonucleotides to the growing oligonucleotide chain can be performed in solution, or continuous rounds of adding oligonucleotides to the growing oligonucleotide chain can be performed directly on, for example, beads. Therefore, during each round of "segmentation", connection (e.g., chemical connection) is performed to attach a new oligonucleotide sequence (e.g., barcode sequence) to expand the library (e.g., barcode library). Therefore, the method of the present disclosure includes at least one "segmentation and merging" step as follows: collect the merged oligonucleotides (e.g., barcodes), distribute them into aliquots, and add additional oligonucleotides (e.g., barcodes), wherein the number of "segmentation and merging" steps indicates the number of different oligonucleotides (e.g., barcodes) added to the growing oligonucleotides. This process results in the generation of a unique oligonucleotide (e.g., barcode) combination. In various embodiments, one, two, three, four, five, six, seven, eight, nine, ten, or more rounds of segmentation and merging are performed. In various embodiments, the disclosed methods produce bead arrays comprising about, at least about, or less than about 1×10 2 , 1×10 3 , 1×10 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 or more unique oligonucleotide sequences attached thereto.
[0050] Thus, in some aspects, the present disclosure provides a method of producing a bead array, the method comprising: (i) attaching a first oligonucleotide to a first population of beads, attaching a second oligonucleotide to a second population of beads, and attaching a third oligonucleotide to a third population of beads, wherein the first oligonucleotide, the second oligonucleotide, and the third oligonucleotide comprise unique nucleotide sequences relative to each other; (ii) combining the first population of beads, the second population of beads, and the third population of beads to produce a first pool; (iii) dividing the first pool into a first plurality of aliquots; (iv) in a first aliquot of the first plurality of aliquots, chemically linking a fourth oligonucleotide to the first oligonucleotide in the presence of a first splint oligonucleotide, wherein the fourth oligonucleotide a splint oligonucleotide that hybridizes to both the fourth oligonucleotide and the first oligonucleotide; chemically ligates to the second oligonucleotide in the presence of a second splint oligonucleotide, wherein the second splint oligonucleotide hybridizes to both the fourth oligonucleotide and the second oligonucleotide; chemically ligates to the third oligonucleotide in the presence of a third splint oligonucleotide, wherein the third splint oligonucleotide hybridizes to both the fourth oligonucleotide and the third oligonucleotide; wherein the first splint oligonucleotide, the second splint oligonucleotide, and the third splint oligonucleotide comprise unique nucleotide sequences relative to each other; in a second aliquot of the first plurality of aliquots, chemically ligates to the first oligonucleotide in the presence of the fourth splint oligonucleotide, wherein the fourth splint oligonucleotide hybridizes to The fifth oligonucleotide is hybridized to both the first oligonucleotide and the second oligonucleotide; chemically linked to the second oligonucleotide in the presence of the fifth splint oligonucleotide, wherein the fifth splint oligonucleotide is hybridized to both the fifth oligonucleotide and the second oligonucleotide; chemically linked to the third oligonucleotide in the presence of the sixth splint oligonucleotide, wherein the sixth splint oligonucleotide is hybridized to both the fifth oligonucleotide and the third oligonucleotide; wherein the fourth splint oligonucleotide, the fifth splint oligonucleotide and the sixth splint oligonucleotide comprise unique nucleotide sequences relative to each other; and in a third aliquot of the first plurality of aliquots, the sixth oligonucleotide is: chemically linked to the first oligonucleotide in the presence of the seventh splint oligonucleotide, wherein the seventh splint oligonucleotide is hybridized to the sixth oligonucleotide and the third oligonucleotide; (v) combining a first aliquot of the first plurality of aliquots, a second aliquot of the first plurality of aliquots, and a third aliquot of the first plurality of aliquots to produce a second pool; (vi) dividing the second pool into a second plurality of aliquots;(vii) in a first aliquot of the second plurality of aliquots, chemically linking the seventh oligonucleotide to the fourth oligonucleotide in the presence of the tenth splint oligonucleotide, wherein the tenth splint oligonucleotide hybridizes with both the seventh oligonucleotide and the fourth oligonucleotide; in a second aliquot of the second plurality of aliquots, chemically linking the eighth oligonucleotide to the fifth oligonucleotide in the presence of the eleventh splint oligonucleotide, wherein the eleventh splint oligonucleotide hybridizes with both the eighth oligonucleotide and the fifth oligonucleotide; and in a third aliquot of the second plurality of aliquots, chemically linking the ninth oligonucleotide to the sixth oligonucleotide in the presence of the twelfth splint oligonucleotide, wherein the twelfth splint oligonucleotide hybridizes with both the ninth oligonucleotide and the sixth oligonucleotide. In various embodiments, step (i) comprises about, at least about, or less than about 10, 20, 50, 100, 200, 500, 1,000, 2,000, 5,000, 10,000, 13,600, 15,000, 20,000, 50,000, 100,000, 200,000, 500,000, 700,000, 1×10; 6 , 2×10 6 , 3×10 6 , 4×10 6 , 5×10 6 , 6×10 6 ,7×10 6 , 8×10 6 or more populations of beads, and each population of beads comprises a unique oligonucleotide attached thereto relative to each other population of beads.
[0051] In other aspects, the present disclosure provides a method for producing a bead array, the method comprising: (i) attaching a first oligonucleotide to one or more beads in a first bead population, attaching a second oligonucleotide to one or more beads in a second bead population, and attaching a third oligonucleotide to one or more beads in a third bead population, wherein the first oligonucleotide, the second oligonucleotide, and the third oligonucleotide comprise unique nucleotide sequences relative to each other; (ii) combining the first bead population, the second bead population, and the third bead population to produce a first pool; (iii) dividing the first pool into a first plurality of aliquots; (iv) in a first aliquot of the first plurality of aliquots, chemically linking a fourth oligonucleotide to the first oligonucleotide, the second oligonucleotide, and the third oligonucleotide; and in a second aliquot of the first plurality of aliquots, chemically linking a fourth oligonucleotide to the first oligonucleotide, the second oligonucleotide, and the third oligonucleotide. (a) chemically linking the first oligonucleotide, the second oligonucleotide, and the third oligonucleotide to the fifth oligonucleotide; (b) chemically linking the first oligonucleotide, the second oligonucleotide, and the third oligonucleotide to the sixth oligonucleotide in the third aliquot of the first plurality of aliquots; (c) combining the first aliquot of the first plurality of aliquots, the second aliquot of the first plurality of aliquots, and the third aliquot of the first plurality of aliquots to produce a second pool; (d) dividing the second pool into a second plurality of aliquots; (e) chemically linking the seventh oligonucleotide to the fourth oligonucleotide in the first aliquot of the second plurality of aliquots; (f) chemically linking the eighth oligonucleotide to the fifth oligonucleotide in the second aliquot of the second plurality of aliquots; and (g) chemically linking the ninth oligonucleotide to the sixth oligonucleotide in the third aliquot of the second plurality of aliquots. In various embodiments, step (i) comprises about, at least about, or less than about 10, 20, 50, 100, 200, 500, 1,000, 2,000, 5,000, 10,000, 13,600, 15,000, 20,000, 50,000, 100,000, 200,000, 500,000, 700,000, 1×10 6 , 2×10 6 , 3×10 6 , 4×10 6 , 5×10 6 , 6×10 6 ,7×10 6 , 8×10 6 or more populations of beads, and each population of beads comprises a unique oligonucleotide attached thereto relative to each other population of beads.
[0052] In any aspect or embodiment of the present disclosure, the last oligonucleotide sequence (e.g., barcode sequence) added to the growing oligonucleotide chain comprises a unique molecular identifier (UMI). In any aspect or embodiment of the present disclosure, the last oligonucleotide sequence (e.g., barcode sequence) added to the growing oligonucleotide chain comprises a poly (T) or poly (A) nucleotide sequence. In some embodiments, the last oligonucleotide sequence (e.g., barcode sequence) added to the growing oligonucleotide chain (which is, for example, a reverse transcription primer) is cleaved from the surface of the bead for sequencing. Therefore, in some embodiments, the present disclosure contemplates the use of a cleavable bond between the bead and the barcoded primer. Cleavable linkers for use in such methods include, but are not limited to, the cleavable linkers described in Bioorg.Med.Chem.2012, 20, 571-582 and Fig.10 The cleavable linker depicted in .
[0053] The length range of the oligonucleotides used in the methods described herein is generally about 5 to about 100 nucleotides. In various embodiments, the length range of the oligonucleotides of the present disclosure is about 5 to about 100 nucleotides, about 5 to about 90 nucleotides, about 5 to about 80 nucleotides, about 5 to about 70 nucleotides, about 5 to about 60 nucleotides, about 5 to about 50 nucleotides, about 5 to about 40 nucleotides, about 5 to about 30 nucleotides, about 5 to about 20 nucleotides, about 5 to about 10 nucleotides, about 10 to about 100 nucleotides, about 10 to about 90 nucleotides, about 10 to about 80 nucleotides, about 10 to about 70 nucleotides, about 10 to about 60 nucleotides, about 10 to about 50 nucleotides, about 10 to about 40 nucleotides, about 10 to about 30 nucleotides, or about 10 to about 20 nucleotides. In additional embodiments, the oligonucleotides of the present disclosure are, are about, are at least about, or are less than about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nucleotides in length.
[0054] connect
[0055] Any method for connecting oligonucleotides can be used in the methods of the present disclosure. In any aspect or embodiment of the present disclosure, chemical connection is used to connect oligonucleotides. In some embodiments, enzymatic connection is used to connect oligonucleotides. In any aspect or embodiment of the present disclosure, a splint oligonucleotide is used during the connection of oligonucleotides. A "splint oligonucleotide" is an oligonucleotide that improves the connection efficiency of oligonucleotides. For example, when two oligonucleotides are connected together, the splint oligonucleotide hybridizes to the ends of each oligonucleotide and then the ends are connected. See, e.g. Figure 3a and 3b. In any aspect or embodiment of the present disclosure, a splint oligonucleotide is used for each connection in the method. In some embodiments, each splint oligonucleotide comprises a unique nucleotide sequence relative to each other splint oligonucleotide. See, e.g. Fig.11 b. In some embodiments, each splint oligonucleotide comprises a semi-random nucleotide sequence. In some embodiments, each oligonucleotide (e.g., barcode) used in the methods of the present disclosure comprises a nucleotide sequence that allows the use of a universal splint oligonucleotide. As used herein, a "universal splint oligonucleotide" refers to a splint oligonucleotide in a population of splint oligonucleotides, wherein each splint oligonucleotide in the population comprises or consists of the same nucleotide sequence. See, e.g. Fig.11 a.
[0056] In some embodiments, the oligonucleotide (e.g., barcode) comprises a modified backbone, such as a phosphorothioate backbone. In various embodiments, reactions that can be performed to produce a phosphate derivative backbone are described in Figure 3 b, wherein the phosphate derivative group may be at the 3' end or the 5' end of either fragment.
[0057] In some embodiments, the method using enzymatic ligation includes the use of a splint oligonucleotide. In some embodiments, the method using chemical ligation includes the use of a splint oligonucleotide. In some embodiments, the method using chemical ligation does not include the use of a splint oligonucleotide. In some embodiments, variables that can increase the efficiency of ligation include, but are not limited to, temperature, buffer, divalent metals [Sci.Rep.2014, 4, 4595], and the use of double-stranded DNA intercalators [(a) Nat.Commun.2016, 6, 7304; (b) PNAS2010, 107, 5288]. In various embodiments, prior to chemical ligation, 3′-modified nucleotides are incorporated using terminal deoxynucleotidyl transferase (TdT).
[0058] In some embodiments, chemically linked oligonucleotides include the synthesis of 3'-5' phosphodiester bonds in the methods disclosed herein. Phosphodiester bonds can be synthesized by methods known in the art. For example, phosphodiester bonds can be synthesized by reacting phosphate or phosphorothioate-terminated nucleosides with hydroxyl-containing nucleosides. The reaction can be promoted by suitable reagents (e.g., 1-fluoro-2,4-dinitrobenzene (DNFB) or 1-cyanoimidazole). In some embodiments, chemically linked oligonucleotides include the synthesis of non-natural backbone bonds between two nucleosides in the methods disclosed herein."Non-natural backbone bonds" are bonds between two nucleotides, rather than naturally occurring 3'-5' phosphodiester bonds. Non-limiting examples of non-natural backbone bonds include phosphoramidates, phosphorothioates, triazoles, squaric acid amides and ureas. Non-natural backbone bonds can be synthesized by methods known in the art. For example, phosphoramidate bonds can be formed by reacting terminal phosphorothioate-modified nucleosides with amine-modified nucleosides. The reaction can be promoted by suitable reagents (e.g., 1-fluoro-2,4-dinitrobenzene (DNFB)). The phosphorothioate bond can be formed by reacting a terminal phosphorothioate-modified nucleoside with a hydroxyl-containing nucleoside. The reaction can be promoted by suitable reagents (e.g., dansyl chloride (dabsyl chloride)). The triazole bond can be formed by an azide-alkyne cycloaddition reaction (e.g., "click reaction"). The azide-alkyne cycloaddition reaction can be catalytic (e.g., by Cu (I)) or non-catalytic. The square acid amide bond can be formed by reacting an amine-modified nucleoside with square acid or its nucleophilic derivative. The formation of square acid amide can be promoted (e.g., using carbodiimide-mediated reaction conditions, such as using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)) or not promoted. Non-limiting examples of methods for synthesizing urea bonds include reacting an amine-modified nucleoside with an activating agent such as 1,1′-carbonyldiimidazole (CDI), reacting an amine-modified nucleoside with an isocyanate-modified nucleoside, or reacting an amine-modified nucleoside with a carbamate-modified nucleoside.
[0059] Exemplary ligation synthesis workflow
[0060] As described herein, in some embodiments, the oligonucleotide comprises a modified backbone. In order to utilize the modified backbone, the method requires modified nucleotide bases at the 5′ and 3′ ends of each oligonucleotide sequence. There are a variety of ways to include modified nucleotide bases at the ends of each oligonucleotide sequence.
[0061] In some embodiments, terminal deoxynucleotidyl transferase (TdT) is used to add modified nucleotide bases to the ends of the oligonucleotide sequence. Figure 5 As shown, the general steps of the connection synthesis workflow include or consist of the following:
[0062] 1. conjugating the first oligonucleotide to a solid phase particle capable of oligonucleotide synthesis (e.g., any particle that can be separated and combined with other particles into a pool), such as but not limited to controlled pore glass (CPG) or beads;
[0063] 2. Incorporating the 3′-modified nucleotide into the first oligonucleotide using TdT;
[0064] 3. chemically ligating the second oligonucleotide to the 5'-orthogonal chemistry and the 3'-orthogonal chemistry of the first oligonucleotide;
[0065] 4. Capping any unreacted 3′-modified nucleotides that failed to ligate;
[0066] 5. Repeat steps 2 to 4 until the nth round, where n=2, 3, 4, 5, 6, 7, 8, 9, 10 or more; and optionally
[0067] 6. cleaving the oligonucleotide (eg, barcode) from the solid phase particle and optionally purifying it; and optionally
[0068] 7. Conjugating the oligonucleotide (eg, barcode) to a second solid phase particle or solid support.
[0069] Before each new connection in the preceding workflow (i.e., before each execution of step (5)), split the pool. (See Figure 1 ). A unique oligonucleotide is then conjugated to each split pool, and the diversity of the oligonucleotide sequences will increase and will depend on the number of rounds of split pools performed. In some embodiments, a washing step is performed after step (1), after step (2), after step (3), after step (4), after step (5), and / or after step (7) to wash away unbound material and / or excess reagent.
[0070] In some embodiments, the modified nucleotide bases are added to the ends of the oligonucleotide sequence in the absence of terminal deoxynucleotidyl transferase (TdT). Figure 6 As shown, the general steps of the connection synthesis workflow include or consist of the following:
[0071] 1. conjugating the first oligonucleotide to a solid phase particle capable of oligonucleotide synthesis (e.g., any particle that can be separated and combined with other particles into a pool), such as but not limited to controlled pore glass (CPG) or beads;
[0072] 2. chemically ligating the second oligonucleotide to the 5′-orthogonal chemistry and the 3′-orthogonal chemistry of the first oligonucleotide;
[0073] 3. Capping any unreacted 3′-modified nucleotides that failed to ligate;
[0074] 4. Repeat steps 2 to 3 until the nth round, where n=2, 3, 4, 5, 6, 7, 8, 9, 10 or more; and optionally
[0075] 5. cleaving the oligonucleotide (eg, barcode) from the solid phase particle and optionally purifying it; and optionally
[0076] 6. Conjugating the oligonucleotide (eg, barcode) to a second solid phase particle or solid support.
[0077] Before each new connection in the preceding workflow (i.e., before each execution of step (3)), split the pool. (See Figure 1 ). A unique oligonucleotide is then conjugated to each split pool, and the diversity of the oligonucleotide sequences will increase and will depend on the number of rounds of split pools performed. In some embodiments, a washing step is performed after step (1), after step (2), after step (3), after step (4), and / or after step (6) to wash away unbound material and / or excess reagent.
[0078] For any of the ligation workflows described herein, there are optional additional steps that can be performed to improve conjugation efficiency and yield. In some embodiments, if R1 and R2 (such as, for example Figure 5 and 6 ) are the only two reactive groups used in the workflow, then R1 on the second oligonucleotide sequence can be capped with a protecting group, and R2 of the second oligonucleotide sequence is conjugated to R1 of the first oligonucleotide sequence. After conjugation is complete, R1 of the second oligonucleotide sequence is then deprotected to enable conjugation of the third oligonucleotide sequence, and the cycle continues. (See Figure 7 ).
[0079] Alternatively, in some embodiments, the number of reactive groups is expanded to four (i.e., R1, R2, R3, R4). For example, a first oligonucleotide may have R1 and R2 reactive handles, wherein R1 is capped or conjugated to a solid support. A second oligonucleotide may have R3 and R4 reactive handles. R2 of the first oligonucleotide may then be conjugated to R3 of the second oligonucleotide. Subsequently, R4 of the second oligonucleotide may then be conjugated to R1 of a third oligonucleotide, the third oligonucleotide having a similar reactive entity as the first oligonucleotide. Here, R2+R3 is orthogonal to R1+R4. (See Figure 8 ).
[0080] To minimize undesired barcodes, in some embodiments, a capping step is included to terminate the synthesis of failed ligations of any workflow disclosed herein. Although the workflows described herein focus on solid support chemical ligation, it is further contemplated that ligation synthesis can also be performed in solution prior to bead attachment. Additionally, although the workflows described herein focus on synthesis prior to bead attachment, in some embodiments, ligation synthesis can also be performed directly on the beads.
[0081] In order to further illustrate the present disclosure, examples are given herein. It should be understood that these examples are provided for illustrative purposes and should not be construed as limiting the scope of the present disclosure.
[0082] Example
[0083] Example 1
[0084] Synthesis of exemplary modified nucleotides for ligation.
[0085] Synthesis of 3′-alkyne dT triphosphate:
[0086]
[0087] Synthesis of 3′-alkyne dA triphosphate:
[0088]
[0089] In this example, two 3'-alkyne modified deoxyribonucleotides that can be used in the chemical ligation methods disclosed herein are synthesized. These modified deoxyribonucleotides can be used to generate triazole bonds (i.e., non-natural backbone bonds) between nucleotides in the chemical ligation disclosed herein.
[0090] Synthesis of 3′-alkyne dT triphosphate: Briefly, deoxythymidine was treated with tert-butyldimethylsilyl chloride (TBDMSCl) in pyridine / DMF to protect the 5′ hydroxyl group. The silylated deoxythymidine was then treated with propargyl bromide and sodium hydride in anhydrous THF to give 3′-alkyne deoxythymidine. Desilylation with tetrabutylammonium fluoride (TBAF) in THF followed by stepwise treatment with phosphorus oxychloride / trimethyl phosphite (POCl3 / PO(OMe)3), tributylammonium pyrophosphate ((Bu3NH)4P2O7), and Bu3N / TEAB gave the desired 3′-alkyne dT triphosphate.
[0091] Synthesis of 3′-alkyne dA triphosphate: Briefly, deoxyadenosine was treated with N,N-dimethylformamide dimethyl acetal to give 10-N,N-dimethylformamidine-protected deoxyadenosine. The protected dA was treated with tert-butyldimethylsilyl chloride (TBDMSCl) in pyridine / DMF to protect the 5′ hydroxyl group. The silylated deoxyadenosine was then treated with propargyl bromide and sodium hydride in anhydrous THF to produce 3′-alkyne deoxyadenosine. Desilylation with tetrabutylammonium fluoride (TBAF) in THF followed by stepwise treatment with phosphorus oxychloride / trimethyl phosphite (POCl3 / PO(OMe)3), tributylammonium pyrophosphate ((Bu3NH)4P2O7), and Bu3N / TEAB gave the desired 3′-alkyne dA triphosphate.
[0092] Example 2
[0093] In this embodiment, arrays of the present invention are produced. The array is produced by synthesizing the first group of 100 unique oligonucleotide beads. Then, chemically connect another 100 unique oligonucleotide barcodes in each segmentation-merging step. After three rounds of segmentation, merging and connection, 100,000,000 barcoded bead pools are produced. Chemical connection can occur on beads or in solution. If in solution, the resulting oligonucleotides are chemically attached to the beads after completing all connection cycles.
[0094] First, three unique oligonucleotide sequences ( Fig.10) and purified. Each of these unique oligonucleotide sequences is then chemically attached to three aldehyde-functionalized bead pools via the 5′ end, i.e., one unique oligonucleotide sequence is attached to one of the three bead pools. Sodium cyanoborohydride is then added to reduce the imine bond formed between the 5′-terminal hydrazine and the aldehyde-functionalized beads. After the oligonucleotide is attached, any small molecule amine is used to cap the excess aldehyde on the beads and further reduced with sodium cyanoborohydride. The beads from the three pools are then combined. TdT enzyme and 3′-alkyne-modified nucleotides are then added to the combined bead pool. After a 3′-alkyne-modified nucleotide is added to the ′OH end of the oligonucleotide attached to the beads, the TdT enzyme and 3′-alkyne-modified nucleotides are washed off with buffer. The combined pool is then randomly divided into three new pools. Unique oligonucleotide sequences with 5′-azide are added to each of the three new bead pools. Click connection is performed with or without a splint. After ligation is complete, the beads are washed multiple times with urea and buffer in buffer to dehybridize any splints and remove unreacted oligonucleotides. Unreacted 3′-alkynes are capped with small molecule azides and washed. Another round of TdT enzyme and 3′-alkyne-modified nucleotides is then added to enable the third oligonucleotide sequence to be ligated to the 3OH terminus of the second oligonucleotide sequence. The process of TdT enzyme and 3′-alkyne-modified nucleotide addition, washing and oligonucleotide ligation and capping steps is repeated until the desired oligonucleotide barcode length is obtained.
[0095] Example 3
[0096] In this embodiment, the method of the present invention is used for space applications. Barcodes are produced on beads, and (1) are directly adhered (for example, by hybridization with surface primers) to solid supports (for example, flow cells), (2) oligonucleotides are released from beads and attached to new beads after purification; beads are then adhered (for example, by hybridization with surface primers) to solid supports, or (3) oligonucleotides are released from beads and adhered (for example, by hybridization with surface primers) to solid supports. The tissue is then placed on a solid support, and nucleic acids from the tissue are captured by oligonucleotides (for example, mRNA is captured by poly (T) capture sequences). The captured nucleic acids can be sequenced in situ or ectopically. For mRNA, cDNA is produced on a solid support.
Claims
1. A method for producing a bead array, comprising: (i) attaching a first oligonucleotide to a first population of beads, a second oligonucleotide to a second population of beads, and a third oligonucleotide to a third population of beads, wherein the first oligonucleotide, the second oligonucleotide, and the third oligonucleotide comprise unique nucleotide sequences relative to each other; (ii) combining the first bead population, the second bead population, and the third bead population to produce a first pool; (iii) dividing the first pool into a first plurality of aliquots; (iv) in a first aliquot of said first plurality of aliquots, adding a fourth oligonucleotide: chemically ligating to the first oligonucleotide in the presence of a first splint oligonucleotide, wherein the first splint oligonucleotide hybridizes to both the fourth oligonucleotide and the first oligonucleotide; chemically linking to the second oligonucleotide in the presence of a second splint oligonucleotide, wherein the second splint oligonucleotide hybridizes to both the fourth oligonucleotide and the second oligonucleotide; and chemically linking to the third oligonucleotide in the presence of a third splint oligonucleotide, wherein the third splint oligonucleotide hybridizes to both the fourth oligonucleotide and the third oligonucleotide; wherein the first splint oligonucleotide, the second splint oligonucleotide, and the third splint oligonucleotide comprise unique nucleotide sequences relative to each other; In a second aliquot of said first plurality of aliquots, a fifth oligonucleotide: chemically ligating to the first oligonucleotide in the presence of a fourth splint oligonucleotide, wherein the fourth splint oligonucleotide hybridizes to both the fifth oligonucleotide and the first oligonucleotide; chemically linking to the second oligonucleotide in the presence of a fifth splint oligonucleotide, wherein the fifth splint oligonucleotide hybridizes to both the fifth oligonucleotide and the second oligonucleotide; and chemically linking to the third oligonucleotide in the presence of a sixth splint oligonucleotide, wherein the sixth splint oligonucleotide hybridizes to both the fifth oligonucleotide and the third oligonucleotide; wherein the fourth splint oligonucleotide, the fifth splint oligonucleotide and the sixth splint oligonucleotide comprise unique nucleotide sequences relative to each other; and in a third aliquot of the first plurality of aliquots, the sixth oligonucleotide: chemically ligating to the first oligonucleotide in the presence of a seventh splint oligonucleotide, wherein the seventh splint oligonucleotide hybridizes to both the sixth oligonucleotide and the first oligonucleotide; chemically ligating to the second oligonucleotide in the presence of an eighth splint oligonucleotide, wherein the eighth splint oligonucleotide hybridizes to both the sixth oligonucleotide and the second oligonucleotide; and chemically linking to the third oligonucleotide in the presence of a ninth splint oligonucleotide, wherein the ninth splint oligonucleotide hybridizes to both the sixth oligonucleotide and the third oligonucleotide; wherein the seventh splint oligonucleotide, the eighth splint oligonucleotide, and the ninth splint oligonucleotide comprise unique nucleotide sequences relative to each other; (v) combining the first aliquot of the first plurality of aliquots, the second aliquot of the first plurality of aliquots, and the third aliquot of the first plurality of aliquots to produce a second pool; (vi) dividing the second pool into a second plurality of aliquots; (vii) in a first aliquot of the second plurality of aliquots, chemically linking a seventh oligonucleotide to a fourth oligonucleotide in the presence of a tenth splint oligonucleotide, wherein the tenth splint oligonucleotide hybridizes to both the seventh oligonucleotide and the fourth oligonucleotide; In a second aliquot of the second plurality of aliquots, chemically linking an eighth oligonucleotide to the fifth oligonucleotide in the presence of an eleventh splint oligonucleotide, wherein the eleventh splint oligonucleotide hybridizes to both the eighth oligonucleotide and the fifth oligonucleotide; and In a third aliquot of the second plurality of aliquots, the ninth oligonucleotide is chemically linked to the sixth oligonucleotide in the presence of a twelfth splint oligonucleotide, wherein the twelfth splint oligonucleotide hybridizes to both the ninth oligonucleotide and the sixth oligonucleotide, and wherein the tenth splint oligonucleotide, the eleventh splint oligonucleotide and the twelfth splint oligonucleotide comprise unique nucleotide sequences relative to each other.
2. A method for producing a bead array, comprising: (i) attaching a first oligonucleotide to one or more beads in a first bead population, a second oligonucleotide to one or more beads in a second bead population, and a third oligonucleotide to one or more beads in a third bead population, wherein the first oligonucleotide, the second oligonucleotide, and the third oligonucleotide comprise unique nucleotide sequences relative to each other; (ii) combining the first bead population, the second bead population, and the third bead population to produce a first pool; (iii) splitting the first pool into a first plurality of aliquots; (iv) in a first aliquot of the first plurality of aliquots, chemically linking a fourth oligonucleotide to the first, second, and third oligonucleotides; in a second aliquot of the first plurality of aliquots, chemically linking a fifth oligonucleotide to the first, second, and third oligonucleotides; and in a third aliquot of the first plurality of aliquots, chemically linking a sixth oligonucleotide to the first, second, and third oligonucleotides; (v) combining the first aliquot of the first plurality of aliquots, the second aliquot of the first plurality of aliquots, and the third aliquot of the first plurality of aliquots to produce a second pool; (vi) splitting the second pool into a second plurality of aliquots; (vii) in a first aliquot of the second plurality of aliquots, chemically linking the seventh oligonucleotide to the fourth oligonucleotide; in a second aliquot of the second plurality of aliquots, chemically linking the eighth oligonucleotide to the fifth oligonucleotide; and in a third aliquot of the second plurality of aliquots, chemically linking the ninth oligonucleotide to the sixth oligonucleotide.
3. The method according to claim 1, further comprising: (viii) combining the first aliquot of the second plurality of aliquots, the second aliquot of the second plurality of aliquots, and the third aliquot of the second plurality of aliquots to produce a third pool; (ix) dividing the third pool into a third plurality of aliquots; (x) in a first aliquot of the third plurality of aliquots, chemically linking a tenth oligonucleotide to the seventh oligonucleotide in the presence of a thirteenth splint oligonucleotide, wherein the thirteenth splint oligonucleotide hybridizes to both the tenth oligonucleotide and the seventh oligonucleotide; In a second aliquot of the third plurality of aliquots, chemically linking an eleventh oligonucleotide to the eighth oligonucleotide in the presence of a fourteenth splint oligonucleotide, wherein the fourteenth splint oligonucleotide hybridizes to both the eleventh oligonucleotide and the eighth oligonucleotide; and In a third aliquot of the third plurality of aliquots, the twelfth oligonucleotide is chemically linked to the ninth oligonucleotide in the presence of the fifteenth splint oligonucleotide, wherein the fifteenth splint oligonucleotide hybridizes to both the twelfth oligonucleotide and the ninth oligonucleotide, and wherein the thirteenth splint oligonucleotide, the fourteenth splint oligonucleotide and the fifteenth splint oligonucleotide comprise unique nucleotide sequences relative to each other.
4. The method according to claim 2, further comprising: (viii) combining the first aliquot of the second plurality of aliquots, the second aliquot of the second plurality of aliquots, and the third aliquot of the second plurality of aliquots to produce a third pool; (ix) splitting the third pool into a third plurality of aliquots; (x) in a first aliquot of the third plurality of aliquots, chemically linking the tenth oligonucleotide to the seventh oligonucleotide; in a second aliquot of the second plurality of aliquots, chemically linking the eleventh oligonucleotide to the eighth oligonucleotide; and in a third aliquot of the second plurality of aliquots, chemically linking the twelfth oligonucleotide to the ninth oligonucleotide.
5. The method of any one of claims 1 to 4, wherein the bead array produced by the method comprises at least about 1×10 6 A unique oligonucleotide sequence is attached to it.
6. The method of claim 5, wherein the bead array produced by the method comprises at least about 1×10 7 A unique oligonucleotide sequence is attached to it.
7. The method of claim 5 or claim 6, wherein the bead array produced by the method comprises at least about 1×10 8 A unique oligonucleotide sequence is attached to it.
8. The method of claim 3, wherein the first splint oligonucleotide, the second splint oligonucleotide, the third splint oligonucleotide, the fourth splint oligonucleotide, the fifth splint oligonucleotide, the sixth splint oligonucleotide, the seventh splint oligonucleotide, the eighth splint oligonucleotide, the ninth splint oligonucleotide, the tenth splint oligonucleotide, the eleventh splint oligonucleotide, the twelfth splint oligonucleotide, the thirteenth splint oligonucleotide, the fourteenth splint oligonucleotide and the fifteenth splint oligonucleotide have the same nucleotide sequence.
9. The method according to any one of claims 1 to 8, wherein an oligonucleotide comprising (i) a poly (T) or poly (A) nucleotide sequence; (ii) one or more gene-specific capture sequences; (iii) one or more universal capture sequences (e.g., a random nucleotide sequence or a semi-random nucleotide sequence) or a combination thereof is chemically linked to the end of each oligonucleotide on each bead in the bead array.
10. The method of any one of claims 1 to 9, wherein (i) comprises about 100 bead populations, each bead population comprising a unique oligonucleotide attached thereto relative to each other bead population.
11. The method of any one of claims 1 to 10, wherein (i) comprises about 13,600 bead populations, and each bead population comprises a unique oligonucleotide attached thereto relative to each other bead population.
12. The method according to any one of claims 1 to 11, wherein the first oligonucleotide, the second oligonucleotide and / or the third oligonucleotide are attached to the one or more beads via a cleavable linker.
13. The method according to any one of claims 1 to 12, wherein prior to the chemical ligation, 3'-modified nucleotides are incorporated using terminal deoxynucleotidyl transferase (TdT).
14. The method according to any one of claims 1 to 12, wherein one or more of the first oligonucleotide, the second oligonucleotide, the third oligonucleotide, the fourth oligonucleotide, the fifth oligonucleotide, the sixth oligonucleotide, the seventh oligonucleotide, the eighth oligonucleotide or the ninth oligonucleotide is a barcode.
15. The method according to any one of claims 1 to 14, wherein each of the first oligonucleotide, the second oligonucleotide, the third oligonucleotide, the fourth oligonucleotide, the fifth oligonucleotide, the sixth oligonucleotide, the seventh oligonucleotide, the eighth oligonucleotide and the ninth oligonucleotide is a barcode.
16. The method of any one of claims 3 to 15, wherein one or more of the tenth oligonucleotide, the eleventh oligonucleotide, or the twelfth oligonucleotide is a barcode.
17. The method according to any one of claims 3 to 15, wherein each of the tenth oligonucleotide, the eleventh oligonucleotide and the twelfth oligonucleotide is a barcode.
18. The method according to any one of claims 14 to 17, wherein the barcode is a spatial barcode.
